Format

Send to

Choose Destination
JCI Insight. 2018 Jul 12;3(13). pii: 121133. doi: 10.1172/jci.insight.121133.

Antibody-modified conduits for highly selective cytokine elimination from blood.

Author information

1
Laboratory for Biomaterials and Drug Delivery, Department of Anesthesiology, and.
2
Department of Medicine, Division of Medicine Critical Care, Harvard Medical School, Boston Children's Hospital, Boston, Massachusetts, USA.
3
Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
4
Department of Cardiac Surgery, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
5
Department of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.

Abstract

Cytokines play an important role in dysregulated immune responses to infection, pancreatitis, ischemia/reperfusion injury, burns, hemorrhage, cardiopulmonary bypass, trauma, and many other diseases. Moreover, the imbalance between inflammatory and antiinflammatory cytokines can have deleterious effects. Here, we demonstrated highly selective blood-filtering devices - antibody-modified conduits (AMCs) - that selectively eliminate multiple specific deleterious cytokines in vitro. AMCs functionalized with antibodies against human vascular endothelial growth factor A or tumor necrosis factor α (TNF-α) selectively eliminated the target cytokines from human blood in vitro and maintained them in reduced states even in the face of ongoing infusion at supraphysiologic rates. We characterized the variables that determine AMC performance, using anti-human TNF-α AMCs to eliminate recombinant human TNF-α. Finally, we demonstrated selective cytokine elimination in vivo by filtering interleukin 1 β from rats with lipopolysaccharide-induced hypercytokinemia.

KEYWORDS:

Anesthesiology; Cytokines; Inflammation; Therapeutics

Supplemental Content

Full text links

Icon for American Society for Clinical Investigation Icon for PubMed Central
Loading ...
Support Center